Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2009-06-01 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MARMANDE (47200), Lot-et-Garonne
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE DU GRAND SUD : revenue, balance sheet and financial ratios
PHARMACIE DU GRAND SUD is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MARMANDE (47200),
this company of category PME
shows in 2017 a revenue of 1.7 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE DU GRAND SUD (SIREN 512650987)
Indicator
2025
2024
2023
2022
2021
2020
2019
2017
2016
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
1 733 050 €
N/C
Net income
100 594 €
87 691 €
40 089 €
469 340 €
434 942 €
208 805 €
87 502 €
147 004 €
159 682 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
232 304 €
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
8.5%
N/C
Revenue and income statement
In 2025, PHARMACIE DU GRAND SUD generates positive net income of 101 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 160 k€ -> 101 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
100 594 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 50%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 62%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
50.477%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
61.938%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE DU GRAND SUD
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2021
2022
2023
2024
2025
Debt ratio
169.563
120.226
106.271
91.016
65.69
38.819
54.541
55.981
50.477
Financial autonomy
33.118
40.323
44.372
48.142
56.429
68.021
58.057
60.329
61.938
Repayment capacity
None
6.05
None
None
None
None
None
None
None
Cash flow / Revenue
None%
9.035%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
50.482025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Average+7 pts over 3 years
In 2025, the debt ratio of PHARMACIE DU GRAND SUD (50.48) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
61.94%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Good
In 2025, the financial autonomy of PHARMACIE DU GRAND SUD (61.9%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 455.08. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
455.078
Liquidity indicators evolution PHARMACIE DU GRAND SUD
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2019
2020
2021
2022
2023
2024
2025
Liquidity ratio
124.486
163.254
370.594
430.633
585.512
641.818
296.147
511.311
455.078
Interest coverage
None
7.588
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
455.082025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of PHARMACIE DU GRAND SUD (455.08) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 129 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 555 days. Excellent situation: suppliers finance 426 days of the operating cycle (retail model).
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
129 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
555 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE DU GRAND SUD
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2019
2020
2021
2022
2023
2024
2025
Operating WCR
0 €
164 674 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
0
33
0
0
0
0
0
0
0
Customer payment term (days)
0
3
0
0
145
169
0
120
129
Supplier payment term (days)
0
50
0
0
464
372
0
373
555
Positioning of PHARMACIE DU GRAND SUD in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE DU GRAND SUD is estimated at
1 597 947 €
(range 1 084 374€ - 2 507 399€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
1084k€1597k€2507k€
1 597 947 €Range: 1 084 374€ - 2 507 399€
NAF 5 année 2025
Valuation method used
Net Income Multiple
100 594 €
×
15.9x
=1 597 948 €
Range: 1 084 375€ - 2 507 400€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE DU GRAND SUD with other companies in the same sector:
Frequently asked questions about PHARMACIE DU GRAND SUD
What is the revenue of PHARMACIE DU GRAND SUD ?
The revenue of PHARMACIE DU GRAND SUD in 2017 is 1.7 M€.
Is PHARMACIE DU GRAND SUD profitable?
Yes, PHARMACIE DU GRAND SUD generated a net profit of 101 k€ in 2025.
Where is the headquarters of PHARMACIE DU GRAND SUD ?
The headquarters of PHARMACIE DU GRAND SUD is located in MARMANDE (47200), in the department Lot-et-Garonne.
Where to find the tax return of PHARMACIE DU GRAND SUD ?
The tax return of PHARMACIE DU GRAND SUD is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE DU GRAND SUD operate?
PHARMACIE DU GRAND SUD operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart